Literature DB >> 8733880

A prospective study of the effect of nonionic contrast media on thyroid function.

J J Conn1, M J Sebastian, D Deam, M Tam, F I Martin.   

Abstract

To observe the effect of iodine in nonionic contrast media on thyroid function, we measured free thyroxine (FT4) and thyroid stimulating hormone (TSH) following nonionic contrast radiography in 73 patients (49 males; 24 females) aged 50 to 84 years, mean 65.7 years. FT4 was significantly (p < 0.01) raised above baseline at 8 weeks but not 4 weeks following contrast injection (mean +/- standard deviation, 17.1 +/- 5.9 and 14.3 +/- 4.0 vs 13.3 +/- 2.7 pmol/L at baseline); however, TSH was significantly (p < 0.03) depressed at both 4 and 8 weeks (1.09 +/- 0.68 and 1.21 +/- 1.56 vs 1.40 +/- 0.90 mIU/L). T3 did not change significantly. FT4 rose by more than 20% in 15/73 and TSH fell by more than 20% in 41/73 compared to a fall of FT4 in 3/73 and a rise in TSH of 8/73 (p < 0.005 and < 0.001, respectively). Two patients became hyperthyroid and in four others either FT4 was elevated or TSH suppressed, one of whom developed atrial fibrillation. Although frank hyperthyroidism following contrast radiography was uncommon, there was a significant trend towards thyroid stimulation rather than suppression after iodine exposure. This may be related to the age of the patients studied.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733880     DOI: 10.1089/thy.1996.6.107

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  15 in total

Review 1.  The use of perchlorate for the prevention of thyrotoxicosis in patients given iodine rich contrast agents.

Authors:  J E Lawrence; S H Lamm; L E Braverman
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

Review 2.  Iodine-induced thyroid dysfunction.

Authors:  Angela M Leung; Lewis E Braverman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-10       Impact factor: 3.243

3.  Percutaneous Coronary Intervention for Chronic Total Occlusion versus Percutaneous Coronary Intervention for Non-Complex Coronary Lesions: Is There a Different Impact on Thyroid Function?

Authors:  Çağın Mustafa Üreyen; Kahraman Coşansu; Mustafa Gökhan Vural; Sait Emir Şahin; Mehmet Akif Çakar; Harun Kılıç; Mustafa Tarık Ağaç; Hüseyin Gündüz; Ramazan Akdemir; Ersan Tatlı
Journal:  Med Princ Pract       Date:  2019-09-20       Impact factor: 1.927

4.  Urinary iodine excretion and serum thyroid function in adults after iodinated contrast administration.

Authors:  Sun Y Lee; Donny L F Chang; Xuemei He; Elizabeth N Pearce; Lewis E Braverman; Angela M Leung
Journal:  Thyroid       Date:  2015-03-23       Impact factor: 6.568

5.  Contrast Induced Thyrotoxicosis in a Patient with New onset Atrial Fibrillation: A Case Report and Review.

Authors:  Jeffrey Adler; Dustin J Colegrove
Journal:  J Atr Fibrillation       Date:  2013-06-30

Review 6.  A review: Radiographic iodinated contrast media-induced thyroid dysfunction.

Authors:  Sun Y Lee; Connie M Rhee; Angela M Leung; Lewis E Braverman; Gregory A Brent; Elizabeth N Pearce
Journal:  J Clin Endocrinol Metab       Date:  2014-11-06       Impact factor: 5.958

Review 7.  Comparative tolerability of contrast media used for coronary interventions.

Authors:  Enrique Esplugas; Angel Cequier; Joan A Gomez-Hospital; Bruno García Del Blanco; Francisco Jara
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

8.  2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction.

Authors:  Tomasz Bednarczuk; Thomas H Brix; Wolfgang Schima; Georg Zettinig; George J Kahaly
Journal:  Eur Thyroid J       Date:  2021-06-16

9.  Effect of iodinated contrast media on thyroid function in adults.

Authors:  Aart J van der Molen; Henrik S Thomsen; Sameh K Morcos
Journal:  Eur Radiol       Date:  2004-02-28       Impact factor: 5.315

Review 10.  Consequences of excess iodine.

Authors:  Angela M Leung; Lewis E Braverman
Journal:  Nat Rev Endocrinol       Date:  2013-12-17       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.